Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease with Rabbit Antithymocyte Globulin
2000
The ISHAGE Guidelines for CD34+ Cell Determination by Flow Cytometry
1996 Standout
First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation
2012
Cancer treatment and survivorship statistics, 2022
2022 Standout
5 Treatment and prognostic factors in acute myeloid leukaemia
1996
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
2015
Posterior Reversible Encephalopathy Syndrome, Part 1: Fundamental Imaging and Clinical Features
2008
Neurotoxicity of calcineurin inhibitors: impact and clinical management
2000
PLGA-based nanoparticles: An overview of biomedical applications
2012 Standout
Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept
2005
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
1996 Standout
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
Posterior Reversible Encephalopathy Syndrome, Part 2: Controversies Surrounding Pathophysiology of Vasogenic Edema
2008
Vascular disorders of the liver # †
2008 Standout
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
1998 Standout
Non‐endocrine late complications of bone marrow transplantation in childhood: part II
2002
Chronic myelogenous leukemia: A review
1996
Chronic Renal Failure after Transplantation of a Nonrenal Organ
2003 Standout
Cyclosporin A Significantly Ameliorates Cortical Damage Following Experimental Traumatic Brain Injury in Rodents
1999
Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups
1994
Development, maintenance and disruption of the blood-brain barrier
2013 Standout
Graft-versus-host disease
2009 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
2005
Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma
2006
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Cancer treatment and survivorship statistics, 2012
2012 Standout
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
2007
Pathophysiology and pharmacologic treatment of acute spinal cord injury*1
2004 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995)
2004
Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria
2009
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells
2001
A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan
2002
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange
2009
Neurological and neuroradiological findings in long‐term survivors of allogeneic bone marrow transplantation
1998
High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.
1993
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Mitoxantrone
1996
Cyclosporine-Induced Hypertension After Transplantation
1994
Sympathetic Neural Mechanisms of Cyclosporine-Induced Hypertension*
1996
Amendment to Clinical Research Projects: Genetic Marking With Retroviral Vectors to Study the Feasibility of Stem Cell Gene Transfer and the Biology of Hematopoietic Reconstitution After Autologous Transplantation in Multiple Myeloma, Chronic Myelogenous Leukemia, or Metastatic Breast Cancer
1993
The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
2017
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease
1994
Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management
2018
Acute Myeloid Leukemia
2015 Standout
Amyloidosis: Pathogenesis and New Therapeutic Options
2011
Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma
1994
The pharmaceutics and delivery of therapeutic polypeptides and proteins
1993
Treatment of the Newly Diagnosed Adult with De Noyo Acute Myeloid Leukemia
1993
Treatment of Primary Progressive Hodgkin’s and Aggressive Non-Hodgkin’s Lymphoma: Is There a Chance for Cure?
2000
Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings
2000 StandoutNobel
Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor
1994
Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma
1999
In vivo hematopoietic stem cell modification by mRNA delivery
2023 StandoutScienceNobel
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
An Updated Definition of Stroke for the 21st Century
2013 Standout
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
1998 Standout
State-of-the-Art Therapeutics: Hodgkin's Lymphoma
2005
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
1999 Standout
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
Hematological Problems in Pediatric Intensive Care
2013 Standout
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
1996
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
1993
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
2013
CI-973, a new platinum derivative with potential antileukemic activity.
1992
Works of DE Reece being referenced
Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia
2000
High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours
1993
High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults
1991
Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy [see comments]
1994
Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin.
1991
Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected] [published erratum appears in Blood 1992 Jun 15;79(12):3397]
1991
Detection of breakpoint cluster region- negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow
1990
Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988
1991
Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy.
1992
Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study.
2010
High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults
1991
Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected] [published erratum appears in Blood 1992 Jun 15;79(12):3397]
1991
High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy
1995
Detection of breakpoint cluster region- negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow
1990